Correction: BMP-non-responsive SCA1+CD73+CD44+ mouse bone marrow derived osteoprogenitor cells respond to combination of VEGF and BMP-6 to display enhanced osteoblastic differentiation and ectopic bone formation (PLoS ONE (2014) 9:7 (e103060) DOI: 10.1371/journal.pone.0103060);BMP-non-responsive Sca1+CD73+CD44+ mouse bone marrow derived osteoprogenitor cells respond to combination of VEGF and BMP-6 to display enhanced osteoblastic differentiation and ectopic bone formation

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Madhu, Vedavathi ^a   Li, Ching Ju ^a   Dighe, Abhijit S ^a   Balian, Gary ^a   Cui, Quanjun ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ACTIVIN RECEPTOR LIKE KINASE 1; ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR; BONE MORPHOGENETIC PROTEIN RECEPTOR 1B; CADM1 PROTEIN; CELL PROTEIN; ENDOGLIN; HERMES ANTIGEN; OPG PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT BONE MORPHOGENETIC PROTEIN 4; RECOMBINANT BONE MORPHOGENETIC PROTEIN 6; RECOMBINANT BONE MORPHOGENETIC PROTEIN 9; RECOMBINANT CYTOKINE; RECOMBINANT VASCULOTROPIN; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; STEM CELL ANTIGEN 1; TRANSCRIPTION FACTOR DLX5; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; BONE MORPHOGENETIC PROTEIN 6; VASCULOTROPIN A;

ALP GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE MINERALIZATION; BONE REMODELING; CELL DIFFERENTIATION; COL1A1 GENE; CONTROLLED STUDY; DLX5 GENE; DRUG EFFECT; DRUG MECHANISM; GENE; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOPROGENITOR CELL; OSTERIX GENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR GENE; RUNX2 GENE; TISSUE ENGINEERING; ANIMAL; BONE MARROW CELL; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; MESENCHYMAL STROMA CELL; METABOLISM; PHYSIOLOGY;

ANIMALS; BONE MARROW CELLS; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEINS; CELL DIFFERENTIATION; CELLS, CULTURED; MESENCHYMAL STROMAL CELLS; MICE; OSTEOGENESIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84904697344     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0211782     Document Type: Erratum

References (43)

1. Bajada S, Marshall MJ, Wright KT, Richardson JB, Johnson WE (2009) Decreased osteogenesis, increased cell senescence and elevated Dickkopf-1 secretion in human fracture non union stromal cells. Bone 45: 726-735.
2. Mathieu M, Rigutto S, Ingels A, Spruyt D, Stricwant N, et al. (2013) Decreased pool of mesenchymal stem cells is associated with altered chemokines serum levels in atrophic nonunion fractures. Bone 53: 391-398.
3. Street J, Bao M, deGuzman L, Bunting S, Peale FV Jr, et al. (2002) Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A 99: 9656-9661. (Pubitemid 34831103)
4. Hausman MR, Schaffler MB, Majeska RJ (2001) Prevention of fracture healing in rats by an inhibitor of angiogenesis. Bone 29: 560-564. (Pubitemid 33124299)
5. Niikura T, Hak DJ, Reddi AH (2006) Global gene profiling reveals a downregulation of BMP gene expression in experimental atrophic nonunions compared to standard healing fractures. J Orthop Res 24: 1463-1471. (Pubitemid 44083262)
6. Fajardo M, Liu CJ, Egol K (2009) Levels of Expression for BMP-7 and Several BMP Antagonists May Play an Integral Role in a Fracture Nonunion: A Pilot Study. Clin Orthop Relat Res 467: 3071-3078.
7. Kloen P, Lauzier D, Hamdy RC (2012) Co-expression of BMPs and BMP-inhibitors in human fractures and non-unions. Bone 51: 59-68.
8. Aspenberg P, Genant HK, Johansson T, Nino AJ, See K, et al. (2010) Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 25: 404-414.
9. Delimar D, Smoljanovic T, Bojanic I (2012) Could the use of bone morphogenetic proteins in fracture healing do more harm than good to our patients? Int Orthop 36: 683.
10. Nauth A, Ristiniemi J, McKee MD, Schemitsch EH (2009) Bone morphogenetic proteins in open fractures: past, present, and future. Injury 40: 27-31.
11. Garrison KR, Shemilt I, Donell S, Ryder JJ, Mugford M, et al. (2010) Bone morphogenetic protein (BMP) for fracture healing in adults. Cochrane Database Syst Rev 6: 1-158.
12. Chou YF, Zuk PA, Chang TL, Benhaim P, Wu BM (2011) Adipose-derived stem cells and BMP2: Part 1. BMP2-treated adipose-derived stem cells do not improve repair of segmental femoral defects. Connect Tissue Res 52: 109-118.
13. Zuk P, Chou YF, Mussano F, Benhaim P, Wu BM (2011) Adipose-derived stem cells and BMP2: Part 2. BMP2 may not influence the osteogenic fate of human adipose-derived stem cells. Connect Tissue Res 52: 119-132.
14. Mizuno D, Agata H, Furue H, Kimura A, Narita Y, et al. (2010) Limited but heterogeneous osteogenic response of human bone marrow mesenchymal stem cells to bone morphogenetic protein-2 and serum. Growth Factors 28: 34-43.
15. Osyczka AM, Diefenderfer DL, Bhargave G, Leboy PS (2004) Different effects of BMP-2 on marrow stromal cells from human and rat bone. Cells Tissues Organs 176: 109-119. (Pubitemid 38199424)
16. Diefenderfer DL, Osyczka AM, Reilly GC, Leboy PS (2003) BMP responsiveness in human mesenchymal stem cells. Connect Tissue Res 44: 305-311. (Pubitemid 36395462)
17. Diefenderfer DL, Osyczka AM, Garino JP, Leboy PS (2003) Regulation of BMP-induced transcription in cultured human bone marrow stromal cells. J Bone Joint Surg Am 85: 19-28. (Pubitemid 36957900)
18. Puleo DA (1997) Dependence of mesenchymal cell responses on duration of exposure to bone morphogenetic protein-2 in vitro. J Cell Physiol 173: 93-101.
19. Hanada K, Dennis JE, Caplan AI (1997) Stimulatory effects of basic fibroblast growth factor and bone morphogenetic protein-2 on osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells. J Bone Miner Res 12: 1606-1614. (Pubitemid 27422361)
20. Jørgensen NR, Henriksen Z, Sørensen OH, Civitelli R (2004) Dexamethasone, BMP-2, and 1, 25-dihydroxyvitamin D enhance a more differentiated osteoblast phenotype: validation of an in vitro model for human bone marrow-derived primary osteoblasts. Steroids 69: 219-226. (Pubitemid 38748717)
21. Kyllönen L, Haimi S, Säkkinen J, Kuokkanen H, Mannerström B, et al. (2013) Exogenously added BMP-6, BMP-7 and VEGF may not enhance the osteogenic differentiation of human adipose stem cells. Growth Factors 31: 141-153.
22. Takagi K, Urist MR (1982) The role of bone marrow in bone morphogenetic protein-induced repair of femoral massive diaphyseal defects. Clin Orthop Relat Res 171: 224-231. (Pubitemid 13217516)
23. Waese EY, Kandel RA, Stanford WL (2008) Application of stem cells in bone repair. Skeletal Radiol 37: 601-608.
24. Steinert AF, Rackwitz L, Gilbert F, Nöth U, Tuan RS (2012) Concise review: the clinical application of mesenchymal stem cells for musculoskeletal regeneration: current status and perspectives. Stem Cells Transl Med 1: 237-247.
25. Cui Q, Dighe AS, Irvine JN (2013) Combined angiogenic and osteogenic factor delivery for bone regenerative engineering. Curr Pharm Des 19: 3374-3383.
26. Peng H, Wright V, Usas A, Gearhart B, Shen HC, et al. (2002) Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J Clin Invest 110: 751-719.
27. Peng H, Usas A, Olshanski A, Ho AM, Gearhart B, et al. (2005) VEGF improves, whereas sFlt1 inhibits, BMP2-induced bone formation and bone healing through modulation of angiogenesis. J Bone Miner Res 20: 2017-2027. (Pubitemid 41532787)
28. Roldan JC, Detsch R, Schaefer S, Chang E, Kelantan M, et al. (2010) Bone formation and degradation of a highly porous biphasic calcium phosphate ceramic in presence of BMP-7, VEGF and mesenchymal stem cells in an ectopic mouse model. J Craniomaxillofac Surg 38: 423-430.
29. Li JZ, Li H, Sasaki T, Holman D, Beres B, et al. (2003) Osteogenic potential of five different recombinant human bone morphogenetic protein adenoviral vectors in the rat. Gene Ther 10: 1735-1743. (Pubitemid 37121045)
30. Kang Q, Sun MH, Cheng H, Peng Y, Montag AG, et al. (2004) Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther 11: 1312-1320. (Pubitemid 39213996)
31. Song K, Krause C, Shi S, Patterson M, Suto R, et al. (2010) Identification of a key residue mediating bone morphogenetic protein (BMP)-6 resistance to noggin inhibition allows for engineered BMPs with superior agonist activity. J Biol Chem 285: 12169-12180.
32. Cui F, Wang X, Liu X, Dighe AS, Balian G, et al. (2010) VEGF and BMP-6 enhance bone formation mediated by cloned mouse osteoprogenitor cells. Growth Factors 28: 306-317.
33. Wang X, Cui F, Madhu V, Dighe AS, Balian G, et al. (2011) Combined VEGF and LMP-1 delivery enhances osteoprogenitor cell differentiation and ectopic bone formation. Growth Factors 29: 36-48.
34. Seamon J, Wang X, Cui F, Keller T, Dighe AS, et al. (2013) Adenoviral Delivery of the VEGF and BMP-6 Genes to Rat Mesenchymal Stem Cells Potentiates Osteogenesis. Bone Marrow Res 2013: 737580.
35. Zhang Y, Madhu V, Dighe AS, Irvine JN Jr, Cui Q (2012) Osteogenic response of human adipose-derived stem cells to BMP-6, VEGF, and combined VEGF plus BMP-6 in vitro. Growth Factors 30: 333-343.
36. Diduch DR, Coe MR, Joyner C, Owen ME, Balian G (1993) Two cell lines from bone marrow that differ in terms of collagen synthesis, osteogenic characteristics, and matrix mineralization. J Bone Joint Surg Am 75: 92-105. (Pubitemid 23064106)
37. Dighe AS, Yang S, Madhu V, Balian G, Cui Q (2012) Interferon gamma and T cells inhibit osteogenesis induced by allogeneic mesenchymal stromal cells. J Orthop Res 31: 227-234.
38. Reed AA, Joyner CJ, Brownlow HC, Simpson AH (2002) Human atrophic fracture non-unions are not avascular. J Orthop Res 20: 593-599. (Pubitemid 34461020)
39. Sarahrudi K, Thomas A, Braunsteiner T, Wolf H, Vécsei V, et al. (2009) VEGF serum concentrations in patients with long bone fractures: a comparison between impaired and normal fracture healing. J Orthop Res 27: 1293-1297.
40. Mentink A, Hulsman M, Groen N, Licht R, Dechering KJ, et al. (2013) Predicting the therapeutic efficacy of MSC in bone tissue engineering using the molecular marker CADM1. Biomaterials 34: 4592-601.
41. Liu Y, Berendsen AD, Jia S, Lotinun S, Baron R, et al. (2012) Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. J Clin Invest 122: 3101-3113.
42. Li G, Corsi-Payne K, Zheng B, Usas A, Peng H, et al. (2009) The dose of growth factors influences the synergistic effect of vascular endothelial growth factor on bone morphogenetic protein 4-induced ectopic bone formation. Tissue Eng Part A 15: 2123-2133.
43. Barbara NP, Wrana JL, Letarte M (1999) Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 274: 584-594.